header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

ACRYLIC BONE CEMENT AS PLATFORMS FOR LOCAL DRUG DELIVERY: THE IMPORTANCE OF RELEASE ENHANCERS

European Bone And Joint Infection Society (EBJIS) 34th Annual Meeting: PART 1



Abstract

Antibiotic-loaded bone cements are used to decrease occurrence of bone infections in cemented arthroplasties and actually being considered as a more cost-effective procedure when compared to cementless implants [1]. However, considering the challenge of treating device-associated infections there is a reduced number of formulations in the market. Response from the industry to medical need is still slow considering the rapid change in the infecting microbial profile and the emergence of multiresistant strains [2]. In this context, the aim of the work is to evaluate the role of lactose (L), as a porogen, on the antibiotic release from bone cement (BC). Levofloxacin (Lev) and minocycline (M) were the selected antibiotics to be individually loaded into BC due to their low cost and potential application in bone infections [3,4].

Two types of matrices were prepared: 1) Loaded with 2.5% of antibiotics (controls) and 2) Loaded with 10% lactose and 2.5% antibiotic. In vitro drug release and microbiological tests against representative strains causative of bone infections were assessed.

Lactose significantly increased the release of both antibiotics. Complete minocycline release after one-week was observed (Fig.1A). Also, lactose increased 3.5-fold the levofloxacin released from BC (Fig.1B).

Furthermore, microbiological studies showed that no interaction was observed between lactose and antibiotic as no decrease in drugs antimicrobial activity was observed (Table 1).

Considering the results, L-BC matrix appears to be a valuable alternative to available formulations. Future work will include testing other antibiotics as well as mixtures of drugs.

Fundação para a Ciência e Tecnologia (Portuguese government) for financial support: EXCL/CTM-NAN/0166/2012 and strategic project PEst-OE/SAU/UI4013/2011.


E-mail: